Safety of cilostazol in peripheral artery disease: A cohort from a primary healthcare electronic database

Jordi Real, M. Catalina Serna, Maria Giner-Soriano, Rosa Forés, Guillem Pera, Esther Ribes, Maite Alzamora, Josep Ramon Marsal, Antonio Heras, Rosa Morros

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

© 2018 The Author(s). Background: Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users. Methods: Population-based cohort study including all individuals older than 40 who initiated cilostazol or pentoxifylline during 2009-2011 in SIDIAP database. The two treatment groups were matched through propensity score (PS). Results: Nine thousand one hundred twenty-nine patients met inclusion criteria and after PS matching, there were 2905 patients in each group. 76% of patients were men, with similar mean ages in both groups (68.8 for cilostazol and 69.4 for pentoxifylline). There were no differences in bleeding, cerebrovascular and cardiovascular events between both groups. Conclusions: Patients treated with cilostazol were different from those treated with pentoxifylline at baseline, so they were matched through PS. We did not find differences between treatment groups in the incidence of bleeding or cardiovascular and cerebrovascular events. Cilostazol should be used with precaution in elderly polymedicated patients.
Original languageEnglish
Article number85
JournalBMC Cardiovascular Disorders
Volume18
Issue number1
DOIs
Publication statusPublished - 8 May 2018

Keywords

  • Arrhythmia
  • Cardiovascular events
  • Cilostazol
  • Coronary artery disease
  • Electronic health records
  • Haemorrhage
  • Pentoxifylline
  • Peripheral artery disease
  • Primary healthcare

Fingerprint Dive into the research topics of 'Safety of cilostazol in peripheral artery disease: A cohort from a primary healthcare electronic database'. Together they form a unique fingerprint.

Cite this